Immupharma Share Discussion Threads

[w1ndjammer] 05/4/2018 09:18

ham3

yes but you keep telling peeps the stock could crash........

you are now advocating holding double the stock over, what could be a

very volatile period. Maybe you have now reversed your bet.........


WJ.

[fuji99] 05/4/2018 09:17

In addition to Lupus treatment, Lupuzor could have multiple applications for various diseases too.
"According to preclinical findings, LupuzorTM may also be effective in other chronic autoimmune pathologies, such as Sjögren's syndrome (dry eye syndrome) or Crohn's disease (an autoimmune disease that causes chronic intestinal inflammation). Fundamental studies on these promising leads are now underway in Sylviane Muller's laboratory."

[benchmark] 05/4/2018 09:14

immy - the best advice I can give you about the new years tax relief is never put off until to-morrow what you can do today because if you do it today and enjoy it then you can do it again to-morrow

[hamhamham1] 05/4/2018 09:10

W1nd. I am talking about how to use your new CGT allowance. Not to double up long term. If it's too hard for you to follow, I can use smaller words if you want?

[rnsday] 05/4/2018 09:10

@flavio_monteiro by the looks of it I don't think he should give his day job up 😂

[ken chung] 05/4/2018 09:10

Silvianne Muller presentation.

[pretax2] 05/4/2018 09:08

Well is it could be a cup and handle chart (no handle yet).
However I'm hoping its going to turn into a ladle.

[w1ndjammer] 05/4/2018 09:07

yep ham3 now telling peeps to double up, ffs

WJ.

[flavio_monteiro] 05/4/2018 09:06

Professional Chartist - TRADER

OH DEAR!

squiresquire5 Apr '18 - 08:08 - 23073 of 23095
0 0 0
I wonder if it reach 125p today or if it will do it tomorrow.

[ny boy] 05/4/2018 09:05

All good here and in thevmarkets, bullish hammer candle stick on the US indicies, April historically a bullish month for equities

In Sylviane we trust!

Ignore the paid derampers

[longshanks] 05/4/2018 09:05

Don't talk about what you don't understand is my advice. Bed 'n' ISA is a standard broker service that most people will sensibly apply to transferring holdings into an ISA from their regular holdings.This comes with a simple fee, a tiny effective spread and bypasses market makers and their short/long book calculations.Why try to finesse the transfer and make a trading profit when you can do the process so straightforwardly.

[che7win] 05/4/2018 09:03

Anyone can see the bowl, charting is a gray area, you can look at charts in many way and on many timescales.

It isn't an exact science.

But the chart does look pretty :-)

[hamhamham1] 05/4/2018 09:02

Teddy. Never comment on peoples driving. kids or charting skills!
Always ends up ugly :)

[hamhamham1] 05/4/2018 08:58

Tell Sid. I was only talking about those who wish to use up their new CGT allowance for existing shares not in optimum products. Not that you can read obviously.

[tell sid] 05/4/2018 08:55

Some of us have enough money not to sell any but just use our full ISA (£20k) and SIPP (£40k) allownces in addition to those we hold elsewhere unlike you Mr burger flipper hamhamham.

[che7win] 05/4/2018 08:55

Teddy,
think my charting is alright, it looked like a bear trap to me yesterday within the bowls sharp rerating,
Healthy retrace before resuming the move up.

Many are using up THIS years ISA today.

Should pop out at 230p.

[hamhamham1] 05/4/2018 08:50

Will be interesting tomorrow (on top of data lock RNS).
Those wishing to make early use the 2018/19 CGT allowance will either, sell up first thing then buy back in new ISA after, or buy new ISA first, hold double for a bit then sell the CGT qualifying shares at a later time/day? I guess that depends if you have double the cash and are confident. This is only a scenario for those wishing to use the new CGT allowance up early. WTFDIK.

[spawny100] 05/4/2018 08:49

Bought back in yet squire? Don't miss the boat lol.

[fuji99] 05/4/2018 08:44

Edit - "The Research Organisation conducting our Lupuzor(TM) pivotal Phase III trial study, that 'database lock' is expected on 6 April 2018, with top line results announced by mid-April 2018." - Coincidently, 6th of April is the start of the tax year meaning institutions will start loading again their portfolios.
How many shares will be left to the PI to pick up - and at what price ? - if they smell the bacon ?

[ny boy] 05/4/2018 08:42

Pharma sector in play, not long before a bid for SHP, one of my biggest holdings behind GSK, hopefully these will become no 1 in the portfolio soon with a buy out on top line final phase 3 results..excitement mounting, ignore the noise. GLA

[flavio_monteiro] 05/4/2018 08:40

LupuzorTM may become the first specific and non-immunosuppressant therapy for lupus, a disabling autoimmune disease that is currently incurable. Discovered by Sylviane Muller's team in the CNRS Immunopathologie et Chimie Thérapeutique laboratory, in Strasbourg, this peptide is the subject of a CNRS patent (granted in 2009) and has already successfully completed phases I and II of its regulatory clinical trials, supervised by ImmuPharma-France. An international phase III pivotal trial1, also managed by this company, will begin in a few days' time in the US when the first patient starts the treatment, before the trial is extended to Europe. Phase III is the last stage in the testing of a candidate drug, before it can be given market approval. The launch of phase III was the subject of a meeting involving around a hundred physicians on December 11-12, in Paris.
Lupus2 is a chronic autoimmune disease that affects more than five million people worldwide (around 30,000 in France), 90% of whom are women. It is characterized by the production of autoantibodies that attack different organs (skin, joints, vascular system, brain, kidneys) and cause inflammation, hence the broad range of possible symptoms: skin lesions, joint pain, thromboses, psychotic episodes, etc. To alleviate this disease with many causes, only palliative treatments are available at present, most of which are non-specific: corticosteroids and immunosuppressants, but they also weaken the immune system. Although they can stop autoimmune attacks, they also render patients highly susceptible to multiple infections. It was therefore urgent to develop a more targeted therapy.

The team led by Sylviane Muller, who received the 2015 CNRS Medal of Innovation3, developed a family of peptides (protein fragments) that can specifically correct dysfunction of the immune system4. One of these peptides, called P1405, proved capable of delaying the development of lupus in affected mice, while preserving their immune systems' ability to fight infective agents. Since then, phase I and II clinical trials have been carried out6 by the company ImmuPharma-France, which holds an exclusive license for the patents that protect this family of peptides, all owned by the CNRS or filed as joint property. During phase II trials, the disease regressed in 62% of patients after 3 months of treatment: this is the best result ever to have been achieved for this pathology.

Following these successes, ImmuPharma-France launched its pivotal phase III trial. In the same way as during the phase IIb trials, the candidate drug will be administered under double-blind conditions once a month by the subcutaneous route, at a rate of 200 µg per injection, but the duration of treatment will be extended to a year, as opposed to 3 months previously. Two hundred patients will be included in this trial, spread across 45 centers (10 in the US and 35 in Europe7). The first patients will be recruited in the US by the end of 2015. In Europe, the trial should be starting in mid-January in the first centers, which include those in France. Recruitment should be completed by mid-2016 and the final results are anticipated at the end of 2017.

The first Investigators' Meeting for the phase III trial took place on December 11 and 12 in Paris, and involved around a hundred American and European physicians.

Once this final phase of clinical trials is completed, and provided the results confirm those of phase IIb, LupuzorTM could be put on the market and subsequently play a central role in the treatment of patients with lupus.

According to preclinical findings, LupuzorTM may also be effective in other chronic autoimmune pathologies, such as Sjögren's syndrome (dry eye syndrome) or Crohn's disease (an autoimmune disease that causes chronic intestinal inflammation). Fundamental studies on these promising leads are now underway in Sylviane Muller's laboratory.

[divinessence] 05/4/2018 08:38

Today or tomorrow could be the awaited 'lockdown' RNS which will propel the share price imv.

[squiresquire] 05/4/2018 08:34

the difference is i have a gain of 20p so far and can buy back in with ease. Which i will do as soon as i think the re-trace is over. That may be today or it may be tomorrow.

[opodio] 05/4/2018 08:23

On monday you will be lucky to renter under 446p


will be up 200%+ on good P3 readout